Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Zuvekas, S. H. Articles by Norquist, G. Search for Related Content PubMed Citation Articles by Zuvekas, S. H. Articles by Norquist, G. Costs, Cost Analysis Managed Care Programs Related Article

Cost Shifting Under Managed Behavioral Health Care

OBJECTIVE: The study examined whether a managed behavioral health care organization (MBHO) shifted treatment costs. METHODS: Four years of claims data (1991-1995) from an insurer that introduced an MBHO in 1992 to control treatment costs were analyzed. Although the MBHO was not at direct financial risk for specialty mental health treatment, it faced incentives related to reputation and contract renewal to shift costs to primary care treatment or prescription drugs. It was hypothesized that if cost shifting occurred, an increase would be noted in the use of psychotropic medications without concurrent use of specialty mental health treatment. Simple t tests and a generalized estimating equations probit specification were used to test this hypothesis. Separate tests were performed for use of any psychotropic medication, any newer antidepressant, and any stimulant in a large employer group that simultaneously implemented parity coverage (75,360 enrollees) and a group of smaller employers that did not (9,228 enrollees). RESULTS: The use of any psychotropic medication rose 64% in relative terms (p<.001) over the four-year period among enrollees of the large employer group and by 87% in the smaller groups (p<.001). In general, there were downward secular trends in the use of psychotropic medications without specialty care. Introduction of the MBHO was not significantly associated with the use of psychotropic medication alone. For newer antidepressants, introduction of the MBHO was associated in the large group with a 2.4 (p=.003) absolute percentage point decrease in medication use alone. CONCLUSIONS: No evidence was found to suggest that the MBHO shifted treatment costs.

Related Article:

January 2007: This Month's Highlights
Psychiatr Serv 2007 58: 7. [Full Text] [PDF]

This article has been cited by other articles:

				R. G. Kathol and Y. Kishi Calculating Treatment Costs in an MBHO Psychiatr Serv, March 1, 2007; 58(3): 413 - 413. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us